Advertisement

NLS Janssen

Drug Development Pharma - July 16, 2015

Priority Review for Janssen Drug

The US Food and Drug Administration (FDA) has approved under priority review Janssen Pharmaceuticals’ New Drug Application (NDA) for the three-month long-acting atypical antipsychotic Invega Trinza. Priority review is a designation for drugs that, if approved, would offer significant improvement in the treatment of serious conditions. In a long-term maintenance trial, 93 percent of patients […]

Drug Development Pharma - June 9, 2015

Janssen Submits BLA to FDA

Genmab A/S’s licensing partner Janssen Biotech, Inc. has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for daratumumab for double refractory multiple myeloma.  The submission is for using daratumumab to treat patients with multiple myeloma who have received at least three different lines of therapy […]

Acquisition - April 7, 2015

Depomed Buys US Rights to Janssen Franchise

Depomed, Inc. has closed the acquisition of the U.S. rights to the NUCYNTA franchise from Janssen Pharmaceuticals, Inc. for $1.05 billion. The NUCYNTA franchise includes NUCYNTA® ER (tapentadol) extended release tablets indicated for the management of pain, including neuropathic pain associated with diabetic peripheral neuropathy (DPN), an immediate release version of tapentadol, for management of moderate to severe […]

Funding - March 25, 2015

Janssen Joins Dementia Project

Johnson & Johnson’s Janssen Pharmaceutical Companies plan to invest $10 million in a new UK government-led global dementia discovery fund for research to find ways to prevent and treat dementia and Alzheimer’s disease. The investment will come through its affiliate venture arm, Johnson & Johnson Innovation – JJDC, Inc. The global Dementia Discovery Fund brings […]

Collaboration - December 15, 2014

Genmab Earns Milestone Fee

Genmab A/S announced it has reached a milestone in its DuoBody technology platform collaboration with Janssen Biotech, Inc., triggering a $3 million payment.  The milestone payment is for pre-clinical progress with a DuoBody product candidate targeting cancer. “This milestone marks further progress in our DuoBody collaboration with Janssen.  There are now 10 bispecific antibody programs […]

Pharma Business - December 2, 2014

Study: Biopharm Has High Risks, Uncertainty

A first-of-its kind comparison of the business risks confronting six key European industries revealed that the biopharmaceutical sector faces the highest level of risk and economic uncertainty.  The study conducted by Deloitte and commissioned by Janssen, compared six industry sectors: the biopharmaceutical industry, commercial aircraft manufacturing, the automotive industry, consumer electronics, food manufacturing and generic […]

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.